SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Share News (PXS)

Share Price Information for Provexis (PXS)

Share Price is delayed by 15 minutes
Get Live Data
0.94    -0.07 (-6.93%)
Bid:
0.80
Ask:
1.08
Spread: 0.28 (35.00%)
Market Cap: £23.69m
PXS Live PriceLast checked at - London Stock Exchange

Intraday Provexis Share Chart

Provexis News

Provexis Raises GBP50,000 To Support International Growth Plans
19 Feb 2021

Provexis Raises GBP50,000 To Support International Growth Plans

Provexis Raises GBP50,000 To Support International Growth Plans

IN BRIEF: Provexis Posts Revenue Rise Due To Fruitflow Demand Increase
29 Jan 2021

IN BRIEF: Provexis Posts Revenue Rise Due To Fruitflow Demand Increase

IN BRIEF: Provexis Posts Revenue Rise Due To Fruitflow Demand Increase

UK TRADING UPDATE SUMMARY: Focusrite Revenue Grows On Strong Demand
17 Dec 2020

UK TRADING UPDATE SUMMARY: Focusrite Revenue Grows On Strong Demand

UK TRADING UPDATE SUMMARY: Focusrite Revenue Grows On Strong Demand

Provexis enters new China distribution agreement
16 Nov 2020

Provexis enters new China distribution agreement

(Sharecast News) - Provexis announced on Monday that it has entered into a distribution agreement for its 'Fruitflow' heart health functional food ing...

Provexis Inks Agreement For Fruitflow+ Omega-3 Distributor In China
16 Nov 2020

Provexis Inks Agreement For Fruitflow+ Omega-3 Distributor In China

Provexis Inks Agreement For Fruitflow+ Omega-3 Distributor In China

UK EARNINGS SUMMARY: Itaconix 2019 Loss Narrows On Strong Revenue Rise
30 Sep 2020

UK EARNINGS SUMMARY: Itaconix 2019 Loss Narrows On Strong Revenue Rise

UK EARNINGS SUMMARY: Itaconix 2019 Loss Narrows On Strong Revenue Rise

Provexis To Purchase Inven2's Antihypertensive Patents
13 Aug 2020

Provexis To Purchase Inven2's Antihypertensive Patents

Provexis To Purchase Inven2's Antihypertensive Patents

Provexis Interim Loss Narrows On Lower Costs, Revenue Growth
31 Dec 2019

Provexis Interim Loss Narrows On Lower Costs, Revenue Growth

Provexis Interim Loss Narrows On Lower Costs, Revenue Growth